SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group.



SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do.



With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing.



For more information, visit our website at www.skbp.com.